%0 Journal Article %A Barratt, Jonathan %A Lafayette, Richard %A Kristensen, Jens %A Stone, Andrew %A Cattran, Daniel %A Flöge, Jürgen %A Tesar, Vladimir %A Trimarchi, Hernán %A Zhang, Hong %A Eren, Necmi %A Paliege, Alexander %A Rovin, Brad H. %T Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy %J Kidney international %V 103 %N 2 %@ 2157-1724 %C New York, NY %I Elsevier %M RWTH-CONV-250008 %P 391-402 %D 2022 %Z Available online 19 October 2022 %F PUB:(DE-HGF)16 %9 Journal Article %U <Go to ISI:>//WOS:000922298000001 %$ pmid:36270561 %R 10.1016/j.kint.2022.09.017 %U https://publications.rwth-aachen.de/record/862041